company background image
ANR logo

Anatara Lifesciences CHIA:ANR Stock Report

Last Price

AU$0.031

Market Cap

AU$7.5m

7D

-29.5%

1Y

n/a

Updated

22 Jun, 2024

Data

Company Financials

ANR Stock Overview

Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia.

ANR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Anatara Lifesciences Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anatara Lifesciences
Historical stock prices
Current Share PriceAU$0.031
52 Week HighAU$0.052
52 Week LowAU$0.021
Beta0.62
11 Month Change-13.89%
3 Month Change-20.51%
1 Year Changen/a
33 Year Change-77.86%
5 Year Change-87.35%
Change since IPO-95.69%

Recent News & Updates

Recent updates

Shareholder Returns

ANRAU BiotechsAU Market
7D-29.5%1.7%0.8%
1Yn/a5.3%10.3%

Return vs Industry: Insufficient data to determine how ANR performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how ANR performed against the Australian Market.

Price Volatility

Is ANR's price volatile compared to industry and market?
ANR volatility
ANR Average Weekly Movementn/a
Biotechs Industry Average Movement10.7%
Market Average Movement8.4%
10% most volatile stocks in AU Market16.2%
10% least volatile stocks in AU Market3.2%

Stable Share Price: ANR's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ANR's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aDavid Brookesanataralifesciences.com

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water.

Anatara Lifesciences Ltd Fundamentals Summary

How do Anatara Lifesciences's earnings and revenue compare to its market cap?
ANR fundamental statistics
Market capAU$7.45m
Earnings (TTM)-AU$1.75m
Revenue (TTM)n/a

-60.5x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANR income statement (TTM)
Revenue-AU$123.18k
Cost of RevenueAU$1.47m
Gross Profit-AU$1.59m
Other ExpensesAU$157.06k
Earnings-AU$1.75m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0091
Gross Margin1,290.47%
Net Profit Margin1,417.97%
Debt/Equity Ratio0%

How did ANR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.